HIV risk and oral pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) in Nairobi: a cross-sectional study

内罗毕注射吸毒者(PWID)的艾滋病毒感染风险和口服暴露前预防(PrEP):一项横断面研究

阅读:4

Abstract

BACKGROUND: Persons who inject drugs (PWID) in Kenya face a high HIV burden (18% prevalence). Although oral pre-exposure prophylaxis (PrEP) is effective for HIV prevention among PWID, its awareness and use remain low. This study assessed HIV acquisition risk, oral PrEP knowledge, and uptake among PWID in Nairobi, Kenya. METHODS: HIV-negative PWID were recruited from four drop-in centers in Nairobi (February–March 2022). HIV risk from sexual and injection practices was measured using the National Drug and Alcohol Research Centre’s HIV Risk-Taking Behavior Scale (HRBS). Oral PrEP awareness and uptake were assessed using the Low PrEP Awareness and Use among PWID tool. Analyses included descriptive statistics, unpaired t-tests (HRBS scores), chi-square tests (PrEP awareness and use), logistic regression (factors associated with PrEP awareness), and Fisher’s exact tests (PrEP uptake), conducted in SPSS version 24. FINDINGS: Among 256 participants, 82.0% were male, 30.1% were on methadone, and 99.2% injected heroin. Mean HIV risk scores indicated moderate risk from injection practices (8.35/25) and sexual practices (11.59/30), totaling 19.94/55. HRBS scores were not associated with PrEP awareness (P = 0.493) or use (P = 0.727). Sexual HIV risk was higher among women than men (12.44/30 vs. 7.3/30; P < 0.001), and among those aged 18–24 versus 25–55 years (23.00/55 vs. 19.35/55; P = 0.016). PrEP awareness was 59.4%, but only 3.9% had ever used PrEP. Men were more likely than women to be aware of PrEP (84.8% vs. 53.8%; P < 0.001) and to have used it (13.0% vs. 1.9%; P < 0.001). CONCLUSION: PWID in Nairobi have a moderate HIV risk, with young and female PWID disproportionately affected. Despite moderate awareness, PrEP uptake is very low. Targeted PrEP education, gender-responsive outreach, and integration of PrEP into harm reduction services are needed to improve uptake. TRIAL REGISTRATION: ClinicalTrials.gov Protocol Record STUDY0001370.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。